

## ASPS/PSF COMMITMENT TO PATIENT EDUCATION, SAFETY AND RESEARCH

Lynn Jeffers, MD, FACS

Past Vice President Health Policy and Advocacy, ASPS

CDRH FDA General and Plastic Surgery Devices

Advisory Committee Meeting

General and Plastic Surgery Devices Panel

March 25-26, 2019

## **ASPS** and The PSF

- Largest plastic surgery specialty organization in the world
- ASPS represents 93 percent of all boardcertified plastic surgeons in the U.S.
- International members from more than 100 countries





## Mission of ASPS and The PSF

### **American Society of Plastic Surgeons (ASPS)**

The mission of ASPS is to advance quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. To support its members in the provision of excellent patient care, ASPS will provide: education, advocacy, practice support and enhanced public awareness of the value of plastic surgery, while fostering the highest professional, ethical and quality standards.

### The Plastic Surgery Foundation (PSF)

The Plastic Surgery Foundation is the **research** arm of ASPS. The mission of The PSF is to foster innovation in plastic surgery and to **improve the quality of life of plastic surgery patients** through research and development, charity care and enhanced **public awareness** of the value of plastic surgery.





# Trusted Partner in Patient Safety

Collaboration with FDA and others:

- National Breast Implant Registry
- PROFILE Registry
- MDEpiNet
- FDA's Network of Experts
- International Collaboration of Breast Registry Activities (ICOBRA)
- FDA Medwatch Partner





**Established** Infrastructure for Patient Safety, Quality, Research

# AMERICAN SOCIETY OF PLASTIC SURGEONS®

Committees/
Taskforces
Patient Safety Committee

Quality and Performance Measurement Committee

**BIA-ALCL Committee** 

Women's Health and Devices Task Force (WHDTF)


Research Funding

Clinical Trials Network

Plastic Surgery Registries Network (PSRN)












NATIONAL BREAST IMPLANT REGISTRY

# **Established History of Implant Science and Education**





# **Commitment to Patient Perspective**

## **Patient Perspective**

- ASPS/PSF Board of Directors
- Women's Health and Devices Task Force
- National Breast Implant Registry
- Measures and Guidelines Workgroups
- Breast Reconstruction Awareness Fund Committee

## Patient Reported Outcomes in Surgery Conference

- AHRQ 2015 and PCORI 2016 Funding
- Breast-Q, FACE-Q, Wound-Q
- PROS in Registries



**Commitment to Patient Advocacy** 

- WHCRA
- BCPEA
- BIA ALCL Coverage
- Partner with State Societies
- Alliances
- Robust advocacy activities

## **Commitment to Physician Education**


- In-Person Clinical Symposia and Plastic Surgery The Meeting
- PRS and PRS Global Open journals
- ASPS Education Network online learning modules
- Digital communications
- Clinical Practice Guidelines
- BIA-ALCL advisories
- BI Safety Resources on ASPS website



## **Commitment to Patient Education**

#### **Patient Education**

- Digital communications
- BI safety resources for patients on the ASPS website
- Patient brochures for plastic surgeons to share with patients
- Informed Consent resources
- Public Education Committee
- Breast Reconstruction Awareness grants



#### Anaplastic Large Cell Lymphoma (ALCL)

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon type of lymphoma that can develop in the scar capsule near saline or silicone breast implants. This disease is currently being investigated as to its relationship with breast implants. The family of ALCL a rare cancer of the immune system, which can occur anywhere in the Based on adverse event reports, the United States Food and Drug Administration (FDA) estimates the total number of cases of BIA-ALCL over 450 cases. It has been noted that the majority of BIA-ALCL patien have a history of a textured-surface device. An exact single-number est of the risk for both textured and non-textured implants is not possible w gel n currently available data. Lifetime risk of BIA-ALCL has been estimated 1:1,000 to 1: 30,000 for women with textured breast implants, and BIArisk is currently under investigation. BIA-ALCL usually involves swelling of the breast at an average of 3 to 14 years after the initial breast implant operation. Most cases were cured by removal of the implant and the capsule surrounding the implant; however, rare cases have required chemotherapy and/or radiation therapy for treatment.

Patients with breast implants should be followed by a surgeon over time and seek professional care for implant-related symptoms such as pain, lumps, swelling, or asymmetry. Patients should monitor their breast implants with routine breast self-exams and follow standard medical recommendations for imaging (e.g. Mammography, Ultrasound, MRI). Abnormal screening results or implant-related symptoms may result in additional expenses for tests and/or procedures to properly diagnose and treat your condition. Tests and procedures could include but may not be limited to: obtaining breast fluid or tissue for pathology and laboratory evaluation, surgery to remove the scar capsule around the breast implant, implant removal, or implant replacements

#### **Calcification:**

the implant and be visible on mammography, as well as

#### Silicone Gel Bleed:

The evidence regarding the likelihood of clinical consequences associated with silicone gel bleed is mixed. Over time, extremely small amounts of silicone

### ADDITIONAL NECESSARY SURGERY (Re-Operations)

Many variable conditions may influence the longterm results of surgery. It is unknown how your tissue may respond or how wound healing will occur after surgery. Secondary surgery may be necessary to perform additional tightening or repositioning of

#### **Capsular Contracture:**

Scar tissue, which forms routinely around the breast implant internally, can tighten and make the breast round, firm, and possibly painful. Excessive firmness of the breasts can occur soon after surgery or years later. The occurrence of symptomatic capsular contracture is not predictable

## **Continued Commitment to...**

- Safety
- Quality
- Research
- Engagement
- Education

...Surgeons and Patients

## Thank you!



